Brincidofovir (CMX001) is an experimental antiviral drug being developed by Chimerix for the treatment of cytomegalovirus.
It also has activity against adenoviruses, BK virus and herpes simplex viruses, and preliminary tests have also shown it to have potential for the treatment of Ebola virus disease.
Brincidofovir is a prodrug of cidofovir.
According to NBC reporting sources, a sample of Mr. Duncan's blood was sent to the company who in-vitro (in the petri dish) added the substance and saw complete cessation of the virus.
Drug developer Chimerix said its experimental Ebola drug has been provided for potential use in patients, sending its shares up more than 9 percent in afternoon trading.
The drug, brincidofovir, received Emergency Investigational New Drug Applications (EINDA) from the U.S. Food and Drug Administration, the company said.




Reply With Quote